TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
US health agency raises 'concern' over AstraZeneca vaccine trial data
A monitoring board had "expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," a statement from the National Institute of Allergy and Infectious Diseases said.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
In this file photo taken on January 09, 2021 boxes of vials of the Oxford/AstraZeneca Covid-19 vaccine are seen in a refridgerator at Ashton Gate Stadium in Bristol, one of seven mass vaccination centres which are set to open next week as Britain continues its vaccination programme against Covid-19. D (Agence France Presse/Andrew Matthews)
A
US government agency Tuesday raised concerns that AstraZeneca may have included out-of-date drug data in information provided during US trials for its Covid-19 vaccine.
A monitoring board had "expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," a statement from the National Institute of Allergy and Infectious Diseases said.
"We urge the company to work with the DSMB (Data and Safety Monitoring Board) to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible."
The statement comes after AstraZeneca said Monday that stage three US trials had showed its Covid-19 vaccine was 79 percent effective at preventing the disease.
AstraZeneca said it was preparing to submit its findings to the US Food and Drug Administration to authorize the shot for emergency use.
The AstraZeneca vaccine is cheaper and easier to store than many of its rivals, but several countries in Europe and other parts of the world last week suspended its use because of isolated cases of blood clots.
